Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by bball67on Dec 28, 2019 2:18pm
188 Views
Post# 30497096

Is it possible?

Is it possible?It's been quite awhile without a second closing for the private placement. There undoubtedly has been year end loss selling putting pressure on the stock. One possibility is that there was not enough demand on the terms of the first closing. Another possibility is that there is something in the works regarding partnership or sale. If something was in the works, legal counsel would prevent a second closing based on material inside information which could not be disclosed to potential investors. The company would not be able to do a press release on why there was no second closing. In effect, if something was going on, the company would have to remain silent. 

Is it possible that top broker is not objective? He just showed up on the scene recently. His comments for each director were extremely negative without one single positive comment for eight or nine people. Do you find that odd? Is it possible that his motivations are not altruistic. Is it possible that he is not just doing a public service. Is it possible that he has a financial interest in this. You can judge all of this based on his response. As a public company CFO, I had a lot of experience calling out hedge funds for their short positions. Is it possible that top broker has ulterior motivations. Judge by his response.
Bullboard Posts